CliffBio
small molecule

CARBOPLATIN

CARBOPLATIN

Loss of exclusivity—loss of exclusivity
CompanyFresenius Kabi →See this company's full patent-cliff portfolio

Drug detail

Brand nameCARBOPLATIN
Active ingredientCARBOPLATIN
Strength150MG/15ML (10MG/ML)
Dosage formINJECTABLE
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalSeptember 2006
Marketing statusDISCN

More from Fresenius Kabi

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.